Open AccessTotal Plasma Homocysteine Level Assessment and Timing of Folate/B 12 Supplementation Prior to Initiation of Pemetrexed‐Based Chemotherapy for Nonsquamous Non‐Small Cell Lung Cancer Patients: An Irrelevant Investigation, an Unnecessary Delay, or Both?
Author(s) -
Singh Navneet,
Maturu Venkata Nagarjuna,
Behera Digambar
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2015-0040
Subject(s) - pemetrexed , medicine , chemotherapy , lung cancer , oncology , cisplatin , schedule , vitamin b12 , plasma homocysteine , homocysteine , pharmacology , computer science , operating system
Usefulness of total plasma homocysteine for predicting toxicity from and optimal duration of folate and vitamin B 12 supplementation prior to initiation of pemetrexed‐based chemotherapy both remain debatable issues following publication of recent data that challenge conventional protocols followed for the same. Randomized trials are needed in an attempt to simplify supportive care schedule during administration of pemetrexed‐based chemotherapy for non‐squamous NSCLC.